<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>An oral tolerance test using a 25-mg dose of <z:chebi fb="1" ids="9907">ursodeoxycholic acid</z:chebi> was carried out in 46 patients with constitutional <z:hpo ids='HP_0002904'>hyperbilirubinemias</z:hpo>: 26 with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e>, 9 with <z:e sem="disease" ids="C0022350" disease_type="Disease or Syndrome" abbrv="">Dubin-Johnson syndrome</z:e>, 7 with <z:e sem="disease" ids="C0220991" disease_type="Disease or Syndrome" abbrv="">Rotor Syndrome</z:e>, 3 with constitutional <z:chebi fb="0" ids="31696">indocyanine green</z:chebi> intolerance, and 1 with <z:e sem="disease" ids="C0268311" disease_type="Disease or Syndrome" abbrv="">Crigler-Najjar syndrome type II</z:e>; they were compared with 14 healthy control subjects </plain></SENT>
<SENT sid="1" pm="."><plain>The integrated area under the curve of increments of serum UDCA above the base line between 0 and 2 h after oral administration was significantly increased in patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> and <z:e sem="disease" ids="C0022350" disease_type="Disease or Syndrome" abbrv="">Dubin-Johnson syndrome</z:e>, whereas it was <z:mpath ids='MPATH_458'>normal</z:mpath> in patients with <z:e sem="disease" ids="C0220991" disease_type="Disease or Syndrome" abbrv="">Rotor syndrome</z:e> and constitutional <z:chebi fb="0" ids="31696">indocyanine green</z:chebi> intolerance </plain></SENT>
<SENT sid="2" pm="."><plain>As the area under the curve reflects the hepatic clearance of intestinally absorbed <z:chebi fb="1" ids="9907">ursodeoxycholic acid</z:chebi> and therefore gives a quantitative estimate of hepatic <z:chebi fb="1" ids="9907">ursodeoxycholic acid</z:chebi> clearance, the hepatic clearance of <z:chebi fb="1" ids="9907">ursodeoxycholic acid</z:chebi> seems to be impaired in patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> and <z:e sem="disease" ids="C0022350" disease_type="Disease or Syndrome" abbrv="">Dubin-Johnson syndrome</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Administration of <z:chebi fb="1" ids="8069">phenobarbital</z:chebi>, 100 mg/day for 2 wk, improved the <z:chebi fb="1" ids="9907">ursodeoxycholic acid</z:chebi> tolerance test in concordance with the reduction in serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> in 9 patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> studied </plain></SENT>
<SENT sid="4" pm="."><plain>If the turnover of <z:chebi fb="1" ids="9907">ursodeoxycholic acid</z:chebi> is representative of that of other <z:chebi fb="1" ids="3098">bile acids</z:chebi>, these findings suggest that the hepatic transport of <z:chebi fb="0" ids="3098">bile acid</z:chebi> is impaired like other <z:chebi fb="5" ids="22563">anions</z:chebi> in patients with certain constitutional <z:hpo ids='HP_0002904'>hyperbilirubinemias</z:hpo> </plain></SENT>
</text></document>